论文信息 - The POLARIX Study: Polatuzumab Vedotin with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) Therapy in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma - 字舞流文

The POLARIX Study: Polatuzumab Vedotin with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) Therapy in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma

R. Greil | J. Burke | G. Salles | L. Sehn | J. Friedberg | C. Flowers | H. Tilly | Yanwen Jiang | K. Izutsu | L. Obéric | M. Trněný | F. Morschhauser | M. Cheung | M. Matasar | N. Mehta-Shah | W. Jurczak | J. Hirata | J. Sharman | C. Herbaux | Ho-Jin Shin | J. Gau | Shinya Rai | G. Hapgood | M. Yan | A. Pinto | Yuqin Song | A. Chauchet | Calvin Lee | E. Munhoz | J. B. Bergua Burgues | Larysa Mykhalska | P. Abrisqueta Costa